Trial · NCT03619902
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale | Imsidolimab | Week 4 | 75.0 | 95% Confidence Interval 34.91 to 96.81 | percentage of participants |
| Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale | Imsidolimab | Week 16 | 75.0 | 95% Confidence Interval 34.91 to 96.81 | percentage of participants |
| Percent Change From Baseline in Body Surface Area of Erythema With Pustules at Week 1, Week 4, and Week 16 | Imsidolimab | Week 1 | -59.63 | Standard Deviation 39.895 | percent change |
| Percent Change From Baseline in Body Surface Area of Erythema With Pustules at Week 1, Week 4, and Week 16 | Imsidolimab | Week 4 | -94.17 | Standard Deviation 10.737 | percent change |
| Percent Change From Baseline in Body Surface Area of Erythema With Pustules at Week 1, Week 4, and Week 16 | Imsidolimab | Week 16 | -97.78 | Standard Deviation 5.443 | percent change |
| Percent Change From Baseline in Modified Japanese Dermatological Association - Severity Index (mJDA-SI) Total Skin Lesions Score at Week 1, Week 4, and Week 16 | Imsidolimab | Week 1 | -25.74 | Standard Deviation 26.369 | percent change |
| Percent Change From Baseline in Modified Japanese Dermatological Association - Severity Index (mJDA-SI) Total Skin Lesions Score at Week 1, Week 4, and Week 16 | Imsidolimab | Week 4 | -55.65 | Standard Deviation 27.157 | percent change |
| Percent Change From Baseline in Modified Japanese Dermatological Association - Severity Index (mJDA-SI) Total Skin Lesions Score at Week 1, Week 4, and Week 16 | Imsidolimab | Week 16 | -62.20 | Standard Deviation 29.757 | percent change |
| Percentage of Participants Achieving a Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) Score of 0 or 1 at Week 1, Week 4, and Week 16 | Imsidolimab | Week 1 | 0.0 | 95% Confidence Interval 0.00 to 52.18 | percentage of participants |
| Percentage of Participants Achieving a Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) Score of 0 or 1 at Week 1, Week 4, and Week 16 | Imsidolimab | Week 4 | 50.0 | 95% Confidence Interval 6.76 to 93.24 | percentage of participants |
| Percentage of Participants Achieving a Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) Score of 0 or 1 at Week 1, Week 4, and Week 16 | Imsidolimab | Week 16 | 75.0 | 95% Confidence Interval 19.41 to 99.37 | percentage of participants |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 1, Week 4, and Week 16 | Imsidolimab | Week 1 | -0.9 | Standard Deviation 0.356 | score on a scale |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 1, Week 4, and Week 16 | Imsidolimab | Week 4 | -6.0 | Standard Deviation 9.08 | score on a scale |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 1, Week 4, and Week 16 | Imsidolimab | Week 16 | -10.7 | Standard Deviation 9.16 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03619902/results